AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17276272
Drug: Topical anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anesthesia with 0.15 mL intracameral placebo (Group 1)
Trial: 9825370
Drug: Propafenone (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone (2 mg/kg over 15 minutes followed by 10 mg/kg over the next 24 hours)
Trial: 9825370
Drug: Amiodarone (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone (300 mg intravenously over 1 hour, followed by 20 mg/kg over the next 24 hours, plus 1,800 mg/day orally, in 3 divided doses)
Trial: 7926530
Drug: Nitrous oxide/oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrous oxide/oxygen inhalation (n = 30)
Trial: 7926530
Drug: Conventional intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional intravenous sedation (pethidine 50 mg, midazolam 2.5 mg) (n = 29)
Trial: 25692479
Drug: TiZr implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TiZr implants
Trial: 24713048
Drug: Ti Grade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ti Grade IV implants
Trial: 24006085
Drug: Gemtuzumab ozogamicin
RxNorm normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Gemtuzumab ozogamicin (GO) in combination with chemotherapy
Trial: 20868428
Drug: G3 -
RxNorm normalized name: IgG3 - Immunoglobulin G3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G3 - Biosilicate® incorporated in a 1% water‐free‐gel (n=59)
Trial: 19066100
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (within 7-24 hours)
Trial: 19066100
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (ultra-early stage < or = 7 h)
Trial: 19066100
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (delayed stage > 24 h)
Trial: 12593901
Drug: Coil removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coil removal prior to treatment
Trial: 11131487
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (cisplatin-based)
Trial: 8350219
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (4.4 mg/L; final content, 11 mg/L)
Trial: 8350219
Drug: Placebo (final
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (final content, 6.7 mg/L)
Trial: 27177859
Drug: Patients reporting
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients reporting primary goal of treatment as 'cure my cancer'
Trial: 30724096
Drug: Elagolix 150
RxNorm normalized name: elagolix 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elagolix 150 mg
Trial: 23885105
Drug: Elagolix 250
RxNorm normalized name: ELAGOLIX
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Elagolix 250 mg
Trial: 12090980
Drug: Intranasal 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal 4% sodium cromoglicate spray
Trial: 12090980
Drug: Intranasal normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal normal saline spray
Trial: 8619016
Drug: Melatonin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin (0.5 mg) for 7 days
Trial: 6119168
Drug: Oxatomide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxatomide (2 mg/kg by mouth)
Trial: 6119168
Drug: Sodium cromoglycate
RxNorm normalized name: Sodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium cromoglycate powder (20 mg by inhalation)
Trial: 6119168
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo preparations
Trial: 31129603
Drug: Electronic cigarettes
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic cigarettes with nicotine (ECwN) plus placebo tablets of varenicline
Trial: 31129603
Drug: Electronic cigarettes
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic cigarettes without nicotine (ECwoN) plus placebo tablets of varenicline
Trial: 31129603
Drug: Electronic cigarettes
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic cigarettes without nicotine (ECwoN) plus 0.5 mg varenicline tablets
Trial: 30235712
Drug: 5, 10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5, 10, 15, 20, and 25 μg epidural sufentanil as an adjuvant with 10 mL of 0.65% ropivacaine
Trial: 26921890
Drug: Medication-specific education
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-specific education (video and written information about the medication prescribed)
Trial: 26921890
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no medication-specific education)
Trial: 26921890
Drug: Medication-specific education
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication-specific education
Trial: 17539693
Drug: Antipsychotic drug
RxNorm normalized name: antipsychotic drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic drug regimens that do not adversely affect major risk factors for CVD
Trial: 12115219
Drug: Triple combination
RxNorm normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple combination of methotrexate (MTX), hydroxychloroquine (HCQ), and sulfasalazine (SSZ)
Trial: 10195337
Drug: Antipsychotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic treatment with neuroleptics
Trial: 8645833
Drug: Ceftriaxone (1-g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (1-g dose)
Trial: 2138532
Drug: GR 38032F
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GR 38032F (16 mg orally thrice daily)
Trial: 6118250
Drug: Ketotifen (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (1 mg b.i.d. orally for 3 days)
Trial: 6118250
Drug: Ketotifen (7-day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (7-day medication)
Trial: 24476082
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) urinary hCG injection
Trial: 24476082
Drug: Subcutaneous (s.c.)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (s.c.) recombinant hCG injection
Trial: 24476082
Drug: hCG injection
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG injection (both i.m. and s.c.)
Trial: 24476082
Drug: hCG injection
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG injection (s.c.)
Trial: 18684076
Drug: Japanese acupuncture
RxNorm normalized name: Japanese encephalitis virus
DrugBank: Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) (DB10769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Japanese acupuncture treatment
Trial: 15999118
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg finasteride/day for 4 weeks prior to surgery
Trial: 15999118
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no finasteride treatment)
Trial: 14600543
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (50 mg.d(-1)) and beta-carotene (20 mg.d(-1)) in subjects with heavy exercise at leisure
Trial: 1460451
Drug: Fluconazole 200
RxNorm normalized name: fluconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole 200 mg oral dose
Trial: 1460451
Drug: Terconazole 80
RxNorm normalized name: terconazole 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terconazole 80 mg vaginal suppository daily for 3 days
Trial: 26823269
Drug: Structured intervention
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured intervention with written stepped-dose reduction (SIW)
Trial: 26823269
Drug: Structured intervention
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured intervention with stepped-dose reduction and follow-up visits (SIF)
Trial: 15923574
Drug: Elderly patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elderly patients receiving any cancer treatment
Trial: 8929750
Drug: Potassium diclofenac
RxNorm normalized name: Diclofenac Potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium diclofenac suspension (Flogan, Merck, 7ml, 105 mg) after food intake (FOOD phase)
Trial: 8929750
Drug: Potassium diclofenac
RxNorm normalized name: Diclofenac Potassium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium diclofenac suspension (Flogan, Merck, 7ml, 105 mg) after gastric acid secretion blockade (OME phase)
Trial: 1754989
Drug: Evening dose
RxNorm normalized name: Jornay PM, (evening dose) 60 mg/24 hr oral capsule, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening dose of dexamethasone (11.00 p.m.)
Trial: 1754989
Drug: Morning dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dose of dexamethasone (08.00 a.m.)
Trial: 31760207
Drug: Real cupping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real cupping therapy (15 minutes, bilaterally at points BL23, BL24, BL25)
Trial: 31760207
Drug: Placebo cupping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cupping therapy
Trial: 26248442
Drug: Masking Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Masking Therapy (Control)
Trial: 15943568
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg hydroxyurea
Trial: 15943568
Drug: 800-900 mg
RxNorm normalized name: guaifenesin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800-900 mg hydroxyurea
Trial: 10485504
Drug: omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 40 mg/d
Trial: 10485504
Drug: lansoprazole 15
RxNorm normalized name: lansoprazole 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 15 mg/d
Trial: 10485504
Drug: omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: omeprazole 20 mg/d
Trial: 1929762
Drug: Clomipramine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine therapy (nonsubstituted group)
Trial: 7037983
Drug: Live RSV
RxNorm normalized name: fecal microbiota, live Enema [Rebyota]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live RSV vaccine
Trial: 26613790
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg chromium supplements
Trial: 10894101
Drug: Respocort (250-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respocort (250-1000 microg per dose; cumulative dose 2000 microg)
Trial: 10894101
Drug: Becloforte (250-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Becloforte (250-1000 microg per dose; cumulative dose 2000 microg)
Trial: 2066844
Drug: Clindamycin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (20 mg/kg per day, three times a day for 10 days)
Trial: 2066844
Drug: Penicillin plus
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin plus rifampin (benzathine penicillin intramuscularly and rifampin 20 mg/kg per day, twice a day for 4 days)
Trial: 7034680
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of gentamicin sulfate and clindamycin phosphate
Trial: 20427960
Drug: Prevention strategies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prevention strategies for cardiorenal syndromes, including identification and amelioration of precipitating factors, optimal management of chronic heart and kidney diseases, and multimodality therapies for end-organ protection.
Trial: 7837862
Drug: Reduced-osmolarity ORS
RxNorm normalized name: Orserdu
DrugBank: Elacestrant (DB06374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-osmolarity ORS (224 mmol/L)
Trial: 2351319
Drug: Cisplatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (100 mg/m2 iv bolus) and 5-fluorouracil (1000 mg/m2/day for 4 days) with allopurinol (900 mg orally, starting 5 days before 5-fluorouracil)
Trial: 22883712
Drug: Clopidogrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel plus aspirin (dual treatment) for seven days
Trial: 22883712
Drug: Aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin alone (monotherapy) for seven days
Trial: 21872933
Drug: Conventional management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional management (CM) - treatment only if threshold ROP developed
Trial: 11172346
Drug: PEG(40kd) IFN
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG(40kd) IFN alpha‐2a 45 microg once weekly
Trial: 11172346
Drug: PEG(40kd) IFN
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG(40kd) IFN alpha‐2a 90 microg once weekly
Trial: 11172346
Drug: PEG(40kd) IFN
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG(40kd) IFN alpha‐2a 180 microg once weekly
Trial: 11172346
Drug: PEG(40kd) IFN
RxNorm normalized name: PEG IFN-beta-1a
DrugBank: Peginterferon beta-1a (DB09122)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG(40kd) IFN alpha‐2a 270 microg once weekly
Trial: 11172346
Drug: IFN alpha‐2a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN alpha‐2a 3 MIU 3 times weekly
Trial: 9426760
Drug: Oxybutynin 5
RxNorm normalized name: oxyBUTYnin 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin 5 mg three times daily
Trial: 21251076
Drug: Chlorhexidine gel
RxNorm normalized name: chlorhexidine Oral Gel
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine gel (0.5%)
Trial: 21796066
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid 5 mg (single intravenous infusion)
Trial: 21796066
Drug: Raloxifene 60
RxNorm normalized name: raloxifene 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 60 mg (daily oral for 6 months)
Trial: 16717032
Drug: Ximelagatran (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran (2 x 24 mg)
Trial: 7050710
Drug: Aspirin (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (0.5 g given three times a day)
Trial: 30390203
Drug: Amlodipine 10
RxNorm normalized name: amlodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine 10 mg/Valsartan 160 mg (A/V)
Trial: 30390203
Drug: Nebivolol 5
RxNorm normalized name: nebivolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 5 mg/Valsartan 160 mg (N/V)
Trial: 26930583
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg artesunate and 135 mg amodiaquine fixed dose formulation
Trial: 23903900
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.2 % ropivacaine at 4 ml/h with a bolus of 0 ml
Trial: 23903900
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.2 % ropivacaine at 0 ml/h with a bolus of 4 ml
Trial: 20336047
Drug: Reamberin in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reamberin in combined treatment
Trial: 18507525
Drug: Needle-free injection
RxNorm normalized name: Stratis Needle-Free Injection Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Needle-free injection device (NFID)
Trial: 16340384
Drug: Levetiracetam (LEV)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam (LEV) at 500 mg twice daily for 2 months, then increased to 1000 mg twice daily for 4 months
Trial: 6754510
Drug: Tolciclate 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolciclate 1% cream and lotion applied twice a day for about 3 weeks
Trial: 6754510
Drug: Clotrimazole 1%
RxNorm normalized name: CLOTRIMAZOLE 1% LOTION
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clotrimazole 1% cream and lotion applied twice a day for about 3 weeks
Trial: 28672098
Drug: Inhaled Budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Budesonide 1000 μg/dose
Trial: 27269956
Drug: Ibudilast (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibudilast (20 mg twice daily followed by 50 mg twice daily)
Trial: 22749817
Drug: HIFU ablation
RxNorm normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIFU ablation with 1 mL of iodized oil
Trial: 14597886
Drug: Nuclear medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nuclear medicine studies and stress echocardiography
Trial: 10360854
Drug: Propofol (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.75 mg/kg for verbal command response)
Trial: 10360854
Drug: Propofol (1.28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.28 mg/kg for tetanic stimulus response)
Trial: 10360854
Drug: Propofol (1.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.01 mg/kg for verbal command response)
Trial: 10360854
Drug: Propofol (1.76
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.76 mg/kg for tetanic stimulus response)
Trial: 10360854
Drug: Propofol (0.98
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (0.98 mg/kg for verbal command response)
Trial: 10360854
Drug: Propofol (1.89
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.89 mg/kg for tetanic stimulus response)
Trial: 1826213
Drug: celiprolol 400
RxNorm normalized name: celiprolol 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celiprolol 400 mg/day
Trial: 27163699
Drug: Taurine supplementation
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Taurine supplementation (2.0 g, 3 times per day for 14 days)
Trial: 27163699
Drug: Placebo (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2.0 g, 3 times per day for 14 days)
Trial: 23032585
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% saline solution) injection
Trial: 9584539
Drug: Special intervention
RxNorm normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Special intervention (psychiatric evaluation plus 1 to 7 sessions of behavioral therapy)
Trial: 2759361
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of 300 ml of water to a meal
Trial: 29908359
Drug: rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rosuvastatin 10 mg daily (n = 72)
Trial: 24171979
Drug: Hemocoagulase solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemocoagulase solution
Trial: 19484759
Drug: Piperacillin/tazobactam (PIP/TAZO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam (PIP/TAZO) 80 mg/kg piperacillin/10 mg/kg tazobactam every 6 hr
Trial: 19484759
Drug: Cefepime (CEF)
DrugBank: Cefepime (DB01413)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefepime (CEF) 50 mg/kg every 8 hr
Trial: 17121552
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine (2.0 mg.kg(‐1))
Trial: 10989266
Drug: MDMA (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (1.5 mg/kg p.o.) with ketanserin (50 mg p.o.)
Trial: 10989266
Drug: MDMA (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDMA (1.5 mg/kg p.o.) alone
Trial: 9077073
Drug: LTB*-combined vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LTB*-combined vaccine
Trial: 7524759
Drug: 30 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 micrograms of recombinant G-CSF per day
Trial: 7524759
Drug: 300 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 micrograms of recombinant G-CSF per day
Trial: 2884855
Drug: Doxazosin, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin, administered once daily
Trial: 2884855
Drug: Prazosin, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin, administered twice daily
Trial: 31782167
Drug: Routine care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine care (daily pyridoxine [50 mg] and psychoeducation)
Trial: 28608739
Drug: AM-101 0.87
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AM-101 0.87 mg/mL